Retatrutide is the injectable triple agonist that hits GLP-1, GIP, and glucagon receptors at once, and it reached up to 24.2 percent average body weight loss in its Phase 2 obesity trial
Individual tolerance to GLP-1s varies but the most common side effects are nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat
Take our quick 2-minute assessment
Certain medications, including acetaminophen and chemotherapy drugs, may interact with glutathione, so consult your doctor if you are on any medication.
Some private health insurance plans include benefits for weight-management drugs while others exclude them entirely
Data were obtained from the Medicare fee-for-service data from Parts A, B and D from April 2013 to December 2019